Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Met
Go back to Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Met| (NASDAQ: RVMD) | Delayed: 188.57 +5.54 (3.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $183.03 | 52 Week High | $ | |||
| Open | $182.61 | 52 Week Low | $ | |||
| Day High | $193.53 | P/E | N/A | |||
| Day Low | $180.00 | EPS | $ | |||
| Volume | 1,602,025 | |||||
